Lexeo Therapeutics, Inc. (LXEO)

NASDAQ: LXEO · Real-Time Price · USD

9.23

+0.23 (2.56%)

At close: Oct 24, 2025, 4:00 PM EDT

9.37

+0.14 (1.52%)

After-hours: Oct 24, 2025, 7:27 PM EDT

Lexeo Therapeutics Employees

Lexeo Therapeutics had 72 employees as of December 31, 2024. The number of employees increased by 14 or 24.14% compared to the previous year.

Employees

72

Change (1Y)

14

Growth (1Y)

24.14%

Revenue / Employee

n/a

Profits / Employee

-$1,585,722

Market Cap

498.40M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	72	14	24.14%
Dec 31, 2023	58	34	141.67%
Dec 31, 2021	24	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

LXEO News

4 days ago - Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering - GlobeNewsWire
8 days ago - Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement - GlobeNewsWire
8 days ago - Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
17 days ago - Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback - Seeking Alpha
18 days ago - Lexeo Therapeutics, Inc. - Special Call - Seeking Alpha
18 days ago - Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy - GlobeNewsWire
2 months ago - Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights - GlobeNewsWire
3 months ago - Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia - GlobeNewsWire